Indaptus Therapeutics, Inc. Announces Management Changes
August 07, 2021 at 02:59 am IST
Share
Following the closing of the Merger, each of Michael Newman, Ph.D., Hoonmo Lee and Brian O'Callaghan were appointed as directors of Indaptus Therapeutics, Inc. As a result, the Company's board of directors consists of a total of eight directors, with Hila Karah and Hoonmo Lee serving as Class I directors, with a term expiring at the Company's annual meeting of stockholders to be held in 2022, Anthony J. Maddaluna, Brian O'Callaghan and William B. Hayes serving as Class II directors, with a term expiring at the Company's annual meeting of stockholders to be held in 2023, and Jeffrey A. Meckler, Michael Newman, Ph.D. and Dr. Roger Pomerantz serving as Class III directors, with a term expiring at the Company's annual meeting of stockholders to be held in 2024. Dr. Roger Pomerantz serves as the Company's Chairman of the Board. In addition, Brian O'Callaghan was appointed to the Audit Committee replacing Dr. Roger Pomerantz, such that the Audit Committee is comprised of William B. Hayes (Chair), Hila Karah and Brian O'Callaghan; Hoonmo Lee was appointed to the Compensation Committee such that the Compensation Committee is comprised of Anthony J. Maddaluna (Chair), William B. Hayes and Hoonmo Lee; Brian O'Callaghan was appointed to the Nominating Committee as Chair replacing Dr. Roger Pomerantz such that the Nominating Committee is comprised of Brian O'Callaghan (Chair), Anthony J. Maddaluna and Hila Karah. Following the closing of the Merger, Michael Newman, Ph.D. was appointed as Chief Scientific Officer.
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Companyâs approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
INDAPTUS THERAPEUTICS, INC. 
